Sanofi acquires US biopharma firm Blueprint Medicines for $9.1 billion

Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio

Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr

Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Remedium unveils Rights Issue post Rs. 182.7 crore UK deal to drive global expansion

The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience

Granules India completes acquisition of Senn Chemicals

Strengthening capabilities in Peptide Therapeutics and CDMO services

AstraZeneca to invest $2.5 billion in new global strategic R&D centre in China

Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai

Indegene launches new center in London

Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals

Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant

India’s biotech economy set to reach a massive $300 bn by 2030: Dr. Jitendra Singh

Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored

Akums expands Industry-Academia ties with NIFTEM-T, Thanjavur collaboration